Can we Avoid the Unnecessary Loss of nephrons in the Management of Small Solid Renal Masses? Additional Clinical Parameters to Predict Benign-malign Distinction

dc.contributor.authorSelvi, Ismail
dc.contributor.authorBasar, Halil
dc.date.accessioned2024-09-29T16:06:09Z
dc.date.available2024-09-29T16:06:09Z
dc.date.issued2021
dc.departmentKarabük Üniversitesien_US
dc.description.abstractObjectives: We aimed to investigate the predictive value of additional parameters for distinguishing benign-malign tumors and to prevent the loss of nephrons in small (<= 4 cm) solid renal masses. Methods: The data of 56 patients underwent partial or radical nephrectomy between September 2009 and December 2017 due to diagnosis of localized renal cell carcinoma were retrospectively analyzed. Demographic datas, histopathological tumor types, neutrophil/lymphocyte ratio (NLR), monocyte/lymphocyte ratio (MLR), platelet/lymphocyte ratio (PLR), red blood cell distribution width (RDW), mean platelet volume (MPV), the Framingham risk score and its components, postoperative follow-up results were recorded. Patients were divided into two groups as benign and malign. Results: Among 56 patients with a median age of 60 (min: 35-max: 74) years, 13 patients had benign and 43 patients had malign pathologies. MLR (p=0.011), NLR (p=0.032), PLR (p=0.006), MPV (p=0.025), eGFR (p=0.019) and the Framingham score (p=0.008) were significantly higher in malign group. Among the components constituting the Framingham score, only presence of smoking (p=0.032), presence of hypertension (p=0.041) and total cholesterol values (p=0.021) were significantly higher. In multivariate analysis, NLR>2.02 (OR:7.184, p=0.037), PLR>109.65 (OR:12.692, p=0.002), MPV>3.44 (OR:10.543, p=0.046) and Framingham score >10.5 (OR:12.287, p=0.007) were found as predictive factors for distinguishing small solid renal masses concerning malignancy. Conclusion: We think that NLR, PLR, MPV and the Framingham scores may be used in the clinical evaluation of small solid renal masses. In this way, we may prevent the unnecessary loss of nephrons in benign masses with suspicion of malignancy.en_US
dc.identifier.doi10.14744/SEMB.2019.95770
dc.identifier.endpage61en_US
dc.identifier.issn1302-7123
dc.identifier.issn1308-5123
dc.identifier.issue1en_US
dc.identifier.pmid33935536en_US
dc.identifier.startpage53en_US
dc.identifier.trdizinid512200en_US
dc.identifier.urihttps://doi.org/10.14744/SEMB.2019.95770
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/512200
dc.identifier.urihttps://hdl.handle.net/20.500.14619/6665
dc.identifier.volume55en_US
dc.identifier.wosWOS:000631645700008en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherKare Publen_US
dc.relation.ispartofMedical Bulletin of Sisli Etfal Hospitalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectFramingham risk scoreen_US
dc.subjectnephron-sparing approachen_US
dc.subjectpredictive valueen_US
dc.subjectserum hemogram parametersen_US
dc.subjectsmall solid renal massesen_US
dc.titleCan we Avoid the Unnecessary Loss of nephrons in the Management of Small Solid Renal Masses? Additional Clinical Parameters to Predict Benign-malign Distinctionen_US
dc.typeArticleen_US

Dosyalar